WHO ICTRP trial
Anlotinib with gemcitabine and cisplatin or anlotinib with penpulimab as…
ChiCTR2200063085 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2200063085 |
|---|---|
| Public title | Anlotinib with gemcitabine and cisplatin or anlotinib with penpulimab as perioperative treatment for patients with muscle-invasive urothelial carcinoma (MIUC) |
| Scientific title | Anlotinib with gemcitabine and cisplatin or anlotinib with penpulimab as perioperative treatment for patients with muscle-invasive urothelial carcinoma (MIUC) |
| Primary sponsor | Fudan University Shanghai Cancer Center |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 2 |
| Countries | China |
| Conditions | Muscle-invasive urothelial carcinoma (MIUC) |
| Interventions | Group 1 :Anlotinib plus cisplatin and gemcitabine (CG);Group 2:Anlotinib + penpulimab |
| Registration date | Aug 30, 2022 |
| Target size | Group 1 :28;Group 2:36 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: